Companies › Akyso Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Psychiatry; next expected readout Oct 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 1 | Opioid Use Disorder | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07064564 | Naltrexone | Phase 1 | Opioid Use Disorder | Psychiatry | Oct 2029 |
| NCT07064564 | Naltrexone | Phase 1 | Opioid Use Disorder | Psychiatry | Oct 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.